RB-W: Zawiadomienie od osoby zobowiązanej
· 8 marca 2022
Krzysztof Mikosz, member of BioMaxima's Supervisory Board, purchased 2,831 ordinary shares on 8 March 2022 via open market trades on GPW. The acquisition occurred at prices ranging from 20.04–20.46 PLN, with a weighted average of 20.25 PLN and total transaction value of approximately 57.4k PLN. This MAR Article 19 disclosure indicates insider confidence in the company at that valuation. However, the historical context is critical: the stock has since declined ~42% from the purchase price (20.25 → 11.8 PLN current), suggesting either market conditions deteriorated significantly post-transaction or the insider's investment thesis underperformed. No material impact on current trading expected, but this signals a past commitment to shareholder value that ultimately faced headwinds. Relevance for current brokers is primarily compliance-driven (full disclosure history) rather than forward-looking.
Kluczowe dane finansowe
-
Krzysztof MikoszInsider Name
Supervisory Board member (organ compliance role, not C-suite executive)
-
Share Purchase (Nabycie)Transaction Type
Open market acquisition; MAR Article 19 mandatory disclosure
-
2022-03-08Transaction Date
Historical disclosure; ~4 years prior to current evaluation date
-
2,831 sharesShares Purchased
Aggregated from 7 separate market purchases at varying prices
-
20.04–20.46 PLNPrice Range
All purchases executed same trading day across normal market hours
-
20.24824 PLN per shareWeighted Average Price
Aggregate calculation: 57,366 PLN ÷ 2,831 shares
-
~57.37k PLNTotal Transaction Value
Approximately €12.2k or $13.4k at 2022 exchange rates
-
Insider paid 20.25 PLN; stock now 11.8 PLNPrice vs. Current
−42% unrealized loss on position purchased 4 years ago
-
XWAR (GPW equities market)Trading Venue
Warsaw Stock Exchange official equity trading system
-
MAR Article 19 Ust. 1 (EU Regulation 596/2014)Regulatory Framework
Mandatory disclosure of PDMRs/persons closely associated; initial notification